This conversation explores the groundbreaking advancements made by Capstan Therapeutics in the field of cell therapy, particularly focusing on their innovative approach to in vivo engineering and targeted lipid nanoparticles. The discussion highlights the company's rapid growth, significant funding, and the potential impact of their technology on treating autoimmune diseases. The conversation also addresses the challenges faced in the biotech industry and the future prospects for Capstan as they move towards clinical trials and potential market entry.

Capstan Therapeutics, cell therapy, mRNA delivery, autoimmune diseases, targeted lipid nanoparticles, in vivo CAR-T, biotech innovation, AbbVie acquisition, chronic illness treatment